FINAL QUIZ

What is the estimated global incidence of intracerebral hemorrhage (ICH) according to recent data?

In which regions are the highest case fatality rates for ICH observed?

What is the primary reason for the higher prevalence and mortality of ICH in low- and middle-income countries?

Which of the following has been validated as an independent predictor of poor outcomes after intracerebral hemorrhage (ICH), even after accounting for baseline ICH volume?

Which post hoc analysis of the ATACH-2 trial suggested that intensive blood pressure reduction is most effective in reducing hematoma expansion under which conditions?

Which clinical predictor has been shown to correlate most reliably with early hematoma expansion (HE) risk, serving as a cornerstone for predicting HE?

Which of the following is a recent pivotal trial that demonstrated the efficacy of a factor Xa-inhibitor anticoagulation reversal agent in patients with ICH?

What was the main outcome of the ANNEXa-I trial in anticoagulated patients with ICH?

Which of the following complications was reported as a significant concern in the ANNEXa-I trial for patients treated with andexanet alfa?

Which surgical technique was shown to be superior to usual care for functional outcomes in the ENRICH trial for ICH management?

What was the primary outcome measure for the ENRICH trial evaluating minimally invasive surgery in ICH?

The SWITCH trial investigates which of the following interventions for large deep ICH?

What is the most appropriate target systolic blood pressure (SBP) for a patient with acute intracerebral hemorrhage according to current evidence from clinical trials like INTERACT2?

Which of the following is considered the most reliable intervention to reverse coagulopathy in patients with ICH due to vitamin K antagonist therapy (such as warfarin)?

In neurointensive care for ICH, why is the early implementation of an external ventricular drain (EVD) indicated in patients with intraventricular hemorrhage (IVH) and significant hydrocephalus?

What option has a low yield for CT angioography indication in the acute phase of ICH?

What small vessels disease marker is the most specific for cerebral amyloid angiopathy?

Which of the following findings would exclude a diagnosis of probable CAA under the Boston Criteria 2.0?

Which trial provided evidence suggesting that restarting antiplatelet therapy after ICH does not significantly increase the risk of recurrent hemorrhage?

What is the most recommended time frame for considering the resumption of anticoagulation therapy in patients with atrial fibrillation after ICH, based on thromboembolic risk?

Which type of anticoagulant is generally preferred when resuming therapy after ICH due to its lower associated risk of recurrent bleeding?

Which imaging modality is considered the most accurate for identifying early hematoma expansion in acute intracerebral hemorrhage (ICH)?

Which NCCT marker has the highest sensitivity for predicting hematoma expansion in acute ICH?

In the context of ICH, what advantage does MRI offer over NCCT for assessing the etiology of the hemorrhage?